-
公开(公告)号：EP2501225A4
公开(公告)日：2013-07-31
申请号：EP10830850
申请日：2010-11-15
申请人： IPSEN PHARMA SAS
发明人： DONG ZHENG XIN , ZHANG JUNDONG
CPC分类号： A61K38/33 , A61K9/0019 , A61K9/0024 , A61K9/08 , A61K38/34 , C07K14/68 , C07K14/69
-
公开(公告)号：EP2462435A4
公开(公告)日：2013-05-01
申请号：EP10807187
申请日：2010-08-05
发明人： ANDERSON DAVID J , DONG XINZHONG , LIU QIN , GUAN YUN
CPC分类号： A61K31/5517 , A61K38/1709 , A61K38/33 , G01N33/566 , G01N2333/726 , G01N2500/00 , G01N2800/2842
-
43.发明公开USE OF BUBUC AND OPTIONALLY EAA-MART1 (26-35) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF HCMV INFECTIONS 审中-公开作为治疗剂BUBUC和可选EAA MART1（26-35）用于治疗HBV或巨细胞病毒感染中的用途
公开(公告)号：EP2197470A2
公开(公告)日：2010-06-23
申请号：EP08802238.9
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/17 , A61K38/33 , A61P31/22 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00
CPC分类号： C07K7/06 , A61K38/00 , C07K14/503 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Tyr-Val-Lys-Arg-Val-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Val-Lys-Arg-Val-Lys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
44.发明公开METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS 有权法性功能障碍与δ阿片受体激动剂化合物的治疗
公开(公告)号：EP1469850A4
公开(公告)日：2008-03-12
申请号：EP03710631
申请日：2003-01-02
发明人： CHANG KWEN-JEN , KING KLIM , BICIUNAS KESTUTIS P , MCNUTT ROBERT W , PENDERGAST WILLIAM , JAN SHYI-TAI
IPC分类号： A61K31/00 , A61K31/445 , A61K31/495 , A61K31/519 , A61K38/33
CPC分类号： C07D241/04 , A61K31/00 , A61K31/445 , A61K31/495 , A61K31/519 , A61K38/33 , A61K2300/00
-
45.发明公开METHODS FOR INCREASING ANALGESIC POTENCY AND ATTENUATING ADVERSE EXCITATORY EFFECTS OF BIMODALLY-ACTING OPIOID AGONISTS BY INHIBITING GM1-GANGLIOSIDE 有权方法以提高镇痛效果并减少有效BIMODALISCH阿片受体激动剂不必要的兴奋作用，通过抑制神经节苷脂
公开(公告)号：EP1370275A4
公开(公告)日：2006-06-07
申请号：EP02733865
申请日：2002-03-19
申请人： EINSTEIN COLL MED
发明人： CRAIN STANLEY M , SHEN KE-FEI
IPC分类号： A61K38/00 , A61K45/06 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/215 , A61K31/4465 , A61K31/451 , A61K31/4748 , A61K31/485 , A61K33/00 , A61K33/04 , A61K38/22 , A61K38/33 , A61K39/395 , A61P25/04 , A61P25/20 , A61P43/00
CPC分类号： A61K33/00 , A61K31/00 , A61K31/215 , A61K38/33 , A61K2039/505 , A61K2300/00
-
46.发明公开COMBINED USE OF KERATINOCYTE GROWTH FACTOR AGONISTS AND GASTRIN COMPOUNDS 审中-公开角质细胞生长因子受体激动剂和连接胃泌素结合使用
公开(公告)号：EP1620464A1
公开(公告)日：2006-02-01
申请号：EP04730429.0
申请日：2004-04-30
发明人： BRAND, Stephen J, , CRUZ, Antonio
IPC分类号： C07K14/595 , C07K14/50 , A61K38/33 , A61K38/18 , C12N15/09 , A01K67/027 , A61P3/10
CPC分类号： C07K14/50 , A01K2217/05 , A01K2267/0362 , A61K38/1825 , A61K38/33 , A61K2300/00
摘要： The invention relates generally to compositions, conjugates, and methods comprising a KGF agonist and a gastrin compound. The compositions can be used in the treatment and/or prevention of conditions for which either a KGF agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, metabolic syndrome and related diseases and disorders, and obesity.
-
47.发明公开
公开(公告)号：EP1363658A2
公开(公告)日：2003-11-26
申请号：EP02714031.8
申请日：2002-02-19
发明人： WITTIG, Burghardt , STEIN, Christoph , SCHÄFER, Michael , SCHROFF, Matthias , JUNGHANS, Claas , KÖNIG MEREDIZ, Sven Andres
IPC分类号： A61K38/33
CPC分类号： A61K38/33 , A61K38/35 , A61K48/00 , A61K48/0075 , A61K2039/53 , C07K14/57509 , C07K14/665 , C07K14/675 , C07K14/69 , C07K14/695 , C07K2319/00
摘要： The invention relates to an agent for calming the sensation of pain, in particular in chronic inflammatory disorders, by the expression of endogenic, neuroendocrine peptides at the inflammation site. The invention relates in particular to the expression of POMC or CRF from locally injected DNA expression constructs, preferably covalently peptide-modified expression constructs.
-
公开(公告)号：EP0926239A3
公开(公告)日：2002-08-28
申请号：EP98310498.5
申请日：1998-12-21
发明人： Hale, John Edward , Heath, William Francis , Heiman, Mark Louis , Schoner, Brigitte Elisabeth , Butler, Jon Paul , Becker, Gerald Wayne , Varshavsky, Alexander David
摘要： The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical compositions comprising beta-lipotropin or fragments and/or analogs thereof, and methods for treating diabetes and complications associated therewith by administration of an effective amount of beta-lipotropin.
-
49.发明公开METHODS OF ENHANCING OPIATE ANALGESIC POTENCY OR DETOXIFYING AN OPIATE ADDICT 失效PROCEDURE放大有效性阿片类镇痛药或阿片类药物成瘾者脱毒
公开(公告)号：EP0711167A4
公开(公告)日：1999-12-22
申请号：EP94924485
申请日：1994-07-22
申请人： EINSTEIN COLL MED
发明人： CRAIN STANLEY , SHEN KE-FEI
IPC分类号： A61K38/22 , A61K31/00 , A61K31/135 , A61K31/485 , A61K38/33 , A61K45/00 , A61K45/06 , A61P25/04 , A61P25/30 , A61P43/00 , G01N33/94 , G01S7/02
CPC分类号： A61K31/00 , A61K31/485 , A61K38/33 , A61K45/06 , G01N33/94 , G01N33/9486 , G01N2500/10 , G01S7/021 , A61K2300/00
摘要： A composition, and methods of enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists or detoxifying and treating an opiate addict comprising the co-administration of a bimodally-acting opioid agonist which activates inhibitory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an excitatory opioid receptor antagonist which selectively inactivates excitatory opioid agonists.
-
50.发明公开METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING DEPENDENCE LIABILITY CAUSED BY EXOGENOUS AND ENDOGENOUS OPIOID AGONISTS 失效程序对同步增长止痛的功效和减少依赖可能性通过，并EXORGENE ENDOGNE阿片受体激动剂引起的
公开(公告)号：EP0808165A4
公开(公告)日：1999-11-24
申请号：EP95929400
申请日：1995-07-18
申请人： EINSTEIN COLL MED
发明人： CRAIN STANLEY M , SHEN KE-FEI
IPC分类号： A61K38/22 , A61K31/00 , A61K31/135 , A61K31/445 , A61K31/485 , A61K38/17 , A61K38/33 , A61K45/06 , A61P25/04 , A61P25/30 , A61P43/00 , G01N33/94
CPC分类号： A61K31/00 , A61K31/137 , A61K31/485 , A61K38/33 , G01N33/94 , G01N33/9486 , G01N2500/10 , Y10S514/811 , Y10S514/812 , A61K31/4468 , A61K31/135 , A61K2300/00
摘要： This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administration of said bimodally-acting opioid agonists comprising the co-administration of a bimodally-acting opioid agonist which activates both inhibitory and excitatory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an opioid receptor antagonist which selectively inactivates excitatory opioid receptor-mediated side effects. This invention also relates to a method of using excitatory opioid receptor antagonists alone to block the undesirable excitatory side effects of endogenous bimodally-acting opioid agonists which may be markedly elevated during chronic pain. This invention further relates to a method of long-term treatment of previously detoxified opiate, cocaine and alcohol addicts utilizing said excitatory opioid receptor antagonists, either alone or in combination with low-dose methadone, to prevent protracted physical dependence, and to compositions comprising an excitatory opioid receptor antagonist of the invention and a bimodally-acting opioid agonist.
-
-
-
-
-
-
-
-
-
搜索结果
69 条记录 (耗时 0.015 秒)
